EU backs AstraZeneca, Daiichi's ENHERTU
In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
11h
Alex Reid was wrongly advised on early vaccination due to a clinical mistake 17 years earlier. The firm said the decision was taken because of a decline in demand for the vaccine.
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...
Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts ...
This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...
AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback